Why is MERCK & CO. stock price going up?
Bulls say
Clinical development
Advancement of tulisokibart into Phase 3 monotherapy for hidradenitis suppurativa would validate TL1A inhibition and position the drug as a potential new growth driver given its strong efficacy and clean safety profile.
Ophthalmology franchise
Remigromig showing vision improvement comparable to the standard anti-VEGF, together with a novel WNT-pathway approach, could expand Merck's ophthalmology portfolio by offering an alternative mechanism for retinal disease treatment.
Antibody-drug conjugate strategy
Management's characterization of SAC-TMT as a differentiated TROP2-directed ADC with a strong bystander effect and manageable toxicity supports its potential as an important lung cancer therapy and as a candidate for combination regimens with immune checkpoint inhibitors.
Market overhang
Loss of exclusivity for Keytruda remains a major overhang on the company's outlook and could exert sustained pressure on revenues despite pipeline progress.
Safety signals
Higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations reported with remigromig versus the comparator raise material safety and adoption concerns that may limit commercial uptake until further analysis is provided.
Clinical execution risk
Prior experience that efficacy can diminish between trial phases highlights the execution risk for late‑stage candidates and means positive mid‑stage results may not guarantee later success.
